COT-23 INITIAL EXPERIENCE OF TREATMENT FOR GLIOBLASTOMA BY NOVO-TTF

PURPOSE: In 2018,Optune (TTF) became available covered by public insurance for patients with glioblastoma,based on the effectiveness of the US EF-14 study (TTF + TMZ (temozolomide) vs. TMZ). There are problems such as use of at least 18 hours a day,behavior restrictions,expensive medical expenses,etc. From the initial use experience of optune in our hospital,we examined the problems of effectiveness and treatment of TTF. METHOD: We examined patient approval rate of TTF use and treatment problems in patients with glioblastoma who started treatment in our department from 2017.11 when TTF became covered by insurance. RESULT: There were 41 patients with primary glioblastoma during the study period (male: female = 25: 16,median age 60 years (22–77)). There are 10 patients with KPS <70 that are not TTF indications (male: female = 7: 3,median age 45.5 (29–64),consent rate 38.5%). For 26 people (63% of the total) excluding 5 patients who participated in clinical trial,we explained that TTF indications,clinical trial results,adverse events,wearing rate should be 75% or more,and that full shaving is required. 10 people wanted to undergo TTF treatment. The consent rate of women is lower than that of men (46.7% vs. 27.3%),there was a tendency to take TTF treatment in young patients. Average wear rates of 5 patients who continued for more than 6 months were 55%,76%,84%,85%,91%,respectively. Use of TTF for 6 months or longer with residual tumor was CR 1 case,PR 1 case,SD 2 cases. Our department policy is to continue for 12 months. One person ends in 12 months,the other continues to use TTF. So far,no adverse events caused by TTF have been observed,though,there were complaints about the weight of the equipment,feeling of binding,restrictions on bathing,etc.,and one person stopped using it in the fifth month. DISCUSSION: The consent rate for TTF use was about 40% as expected,and 80% of patients with an average wearing rate of 75% or more. TTF can generally continue once the patient is convinced and begins to use,but seems to be severely restricted in behavior in patients with paralysis. There is no profound data on TTF in Japan,and it is necessary to collect data at multiple facilities and clarify the effectiveness and safety in the future.